ClinicalTrials.gov
public full text
Public Domain
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dupilumab De-escalation in Pediatric Atopic Dermatitis#835866
- Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)#982638
- Severity bands for atopic dermatitis measures: analysis from adult dupilumab randomized clinical trials / Andreas Wollenberg, Eric L. Simpson, Yael A. Leshem, Alain Taïeb, Norito Katoh, Jingdong Chao, Ana B. Rossi, Amy H. Praestgaard#783932
- Therapeutic Modulation of Dupilumab in Patients with Severe Atopic Dermatitis: Clinical Effectiveness in Real Life#625563
- Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis#807778
Record · ID 866564
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive